Last reviewed · How we verify

LNG-IUS — Competitive Intelligence Brief

LNG-IUS (LNG-IUS) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Intrauterine contraceptive device (hormonal). Area: Contraception / Reproductive Health.

marketed Intrauterine contraceptive device (hormonal) Progesterone receptor (via levonorgestrel) Contraception / Reproductive Health Small molecule Live · refreshed every 30 min

Target snapshot

LNG-IUS (LNG-IUS) — University of Texas Southwestern Medical Center. LNG-IUS is a levonorgestrel-releasing intrauterine system that provides long-acting reversible contraception by releasing a synthetic progestin directly into the uterus.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
LNG-IUS TARGET LNG-IUS University of Texas Southwestern Medical Center marketed Intrauterine contraceptive device (hormonal) Progesterone receptor (via levonorgestrel)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Intrauterine contraceptive device (hormonal) class)

  1. University of Texas Southwestern Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LNG-IUS — Competitive Intelligence Brief. https://druglandscape.com/ci/lng-ius. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: